Sigilon Therapeutics

Rogerio Vivaldi, M.D., President and CEO

Oct. 11 | 1:45pm | Oxford Biomedica Ballroom  

Cambridge, MA

In-person Presentation 

Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce crucial proteins, enzymes, or other therapeutic molecules needed by patients living with chronic diseases such as lysosomal diseases and diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson and Robert Langer of the Massachusetts Institute of Technology. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions